HomeLarge Type Edition
HOME ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Services
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
PubMed
Right arrow PubMed Citation
The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 57:M414-M418 (2002)
© 2002 The Gerontological Society of America

The Impact of the Use of Statins on the Prevalence of Dementia and the Progression of Cognitive Impairment

Ihab Hajjara, Jeannie Schumperta, Victor Hirtha, Darryl Wielanda and G. Paul Eleazera

a Palmetto Health Alliance/University of South Carolina, Columbia

Ihab Hajjar, Clinical Assistant Professor, Department of Internal Medicine, Division of Geriatrics, Palmetto Health Alliance/University of South Carolina, 9 Medical Park, Suite 230, Columbia, SC 29203 E-mail: ihab.hajjar{at}palmettohealth.org.

Background. Previous evidence suggests that treatment with 3-hydroxy-3-methylglutaryl-coenzyme-A reductase inhibitors (statins) has a positive impact on dementia. We decided to investigate the association between the use of statins and the prevalence of dementia and statins' impact on the progression of cognitive impairment.

Methods. This is a case-control and a retrospective cohort study of a community-based ambulatory primary care geriatric practice. We included a convenience sample of all patients (N = 655, mean age 78.7 ± 0.3 years, 85% Caucasian, 74% women) with hypercholesterolemia or dementia, or using statins. We compared those using statins with those who do not with respect to the clinical diagnosis of dementia and its subtypes and the progression of cognitive impairment.

Results. At the initial visit, 35% had dementia, and 17% were using statins. After covariate adjustments, patients on statins were less likely to have dementia (odds ratio [OR] for dementia based on composite definition = 0.23; 95% confidence interval [CI] [0.1–0.56], p = .001, OR Alzheimer's disease = 0.37; 95% CI [0.19–0.74], p = .005, OR vascular dementia = 0.25; 95% CI [0.08–0.85], p = .027). At follow-up, patients on statins showed an improvement on their Mini-Mental Status Examination score by 0.7 ± 0.4 compared to a decline by 0.5 ± 0.3 in controls, p = .025 (OR for no change or improvement on statins = 2.81; 95% CI [1.02–8.43], p = .045) and scored higher on the Clock Drawing Test (difference of 1.5 ± 0.1, p = .036).

Conclusions. The use of statins is associated with a lower prevalence of dementia and has a positive impact on the progression of cognitive impairment.




This article has been cited by other articles:


Home page
J. Neurol. Neurosurg. PsychiatryHome page
L. Sparks
Statins and cognitive function
J. Neurol. Neurosurg. Psychiatry, January 1, 2009; 80(1): 1 - 2.
[Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
M D M Haag, A Hofman, P J Koudstaal, B H C Stricker, and M M B Breteler
Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study
J. Neurol. Neurosurg. Psychiatry, January 1, 2009; 80(1): 13 - 17.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
Z. Arvanitakis, J. A. Schneider, R. S. Wilson, J. L. Bienias, J. F. Kelly, D. A. Evans, and D. A. Bennett
Statins, incident Alzheimer disease, change in cognitive function, and neuropathology
Neurology, May 6, 2008; 70(19_Part_2): 1795 - 1802.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
J Ellul, N Archer, C M L Foy, M Poppe, H Boothby, H Nicholas, R G Brown, and S Lovestone
The effects of commonly prescribed drugs in patients with Alzheimer's disease on the rate of deterioration
J. Neurol. Neurosurg. Psychiatry, March 1, 2007; 78(3): 233 - 239.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
T. D. Rea, J. C. Breitner, B. M. Psaty, A. L. Fitzpatrick, O. L. Lopez, A. B. Newman, W. R. Hazzard, P. P. Zandi, G. L. Burke, C. G. Lyketsos, et al.
Statin Use and the Risk of Incident Dementia: The Cardiovascular Health Study
Arch Neurol, July 1, 2005; 62(7): 1047 - 1051.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
C. Reitz, J. Luchsinger, M. -X. Tang, J. Manly, and R. Mayeux
Impact of plasma lipids and time on memory performance in healthy elderly without dementia
Neurology, April 26, 2005; 64(8): 1378 - 1383.
[Abstract] [Full Text] [PDF]


Home page
Arch Gen PsychiatryHome page
P. P. Zandi, D. L. Sparks, A. S. Khachaturian, J. Tschanz, M. Norton, M. Steinberg, K. A. Welsh-Bohmer, J. C. S. Breitner, and for the Cache County Study Investigators
Do Statins Reduce Risk of Incident Dementia and Alzheimer Disease?: The Cache County Study
Arch Gen Psychiatry, February 1, 2005; 62(2): 217 - 224.
[Abstract] [Full Text] [PDF]


Home page
Arch NeurolHome page
C. Reitz, M.-X. Tang, J. Luchsinger, and R. Mayeux
Relation of Plasma Lipids to Alzheimer Disease and Vascular Dementia
Arch Neurol, May 1, 2004; 61(5): 705 - 714.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
I. Bjorkhem and S. Meaney
Brain Cholesterol: Long Secret Life Behind a Barrier
Arterioscler Thromb Vasc Biol, May 1, 2004; 24(5): 806 - 815.
[Abstract] [Full Text]


Home page
J. Lipid Res.Home page
N. B. Chauhan
Membrane dynamics, cholesterol homeostasis, and Alzheimer's disease
J. Lipid Res., November 1, 2003; 44(11): 2019 - 2029.
[Abstract] [Full Text]


Home page
Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
V. Suryadevara, S. G. Storey, W. S. Aronow, and C. Ahn
Association of Abnormal Serum Lipids in Elderly Persons With Atherosclerotic Vascular Disease and Dementia, Atherosclerotic Vascular Disease Without Dementia, Dementia Without Atherosclerotic Vascular Disease, and No Dementia or Atherosclerotic Vascular Disease
J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2003; 58(9): M859 - 861.
[Abstract] [Full Text] [PDF]


Home page
JAMAHome page
S. A. Shumaker, C. Legault, S. R. Rapp, L. Thal, R. B. Wallace, J. K. Ockene, S. L. Hendrix, B. N. Jones III, A. R. Assaf, R. D. Jackson, et al.
Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial
JAMA, May 28, 2003; 289(20): 2651 - 2662.
[Abstract] [Full Text] [PDF]


Home page
Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
S. Ghosh and W. S. Aronow
Utilization of Lipid-Lowering Drugs in Elderly Persons With Increased Serum Low-Density Lipoprotein Cholesterol Associated With Coronary Artery Disease, Symptomatic Peripheral Arterial Disease, Prior Stroke, or Diabetes Mellitus Before and After an Educational Program on Dyslipidemia Treatment
J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2003; 58(5): M432 - 435.
[Abstract] [Full Text] [PDF]


Home page
Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
W. A. Banks and J. E. Morley
Memories Are Made of This: Recent Advances in Understanding Cognitive Impairments and Dementia
J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2003; 58(4): M314 - 321.
[Full Text] [PDF]


Home page
Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
J. E. Morley
Editorial: Hot Topics in Geriatrics
J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2003; 58(1): M30 - 36.
[Full Text] [PDF]


Home page
Journals of Gerontology Series A: Biological Sciences and Medical SciencesHome page
W. S. Aronow
Guest Editorial: Should Hypercholesterolemia in Older Persons Be Treated to Reduce Cardiovascular Events?
J. Gerontol. A Biol. Sci. Med. Sci., July 1, 2002; 57(7): M411 - 413.
[Full Text]




HOME ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by The Gerontological Society of America.